Unknown

Dataset Information

0

Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin.


ABSTRACT: To evaluate the efficacy and safety of titrated canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin and sitagliptin.In this randomized, double-blind study, patients with T2DM (N = 218) on metformin ?1500 mg/day and sitagliptin 100 mg received canagliflozin 100 mg or placebo. After 6 weeks, the canagliflozin dose was increased from 100 to 300 mg (or from placebo to matching placebo) if all of the following criteria were met: baseline estimated glomerular filtration rate ?70 ml/min/1.73 m(2) ; fasting self-monitored blood glucose ?5.6 mmol/l (?100 mg/dl); and no volume depletion-related adverse events (AEs) within 2 weeks before dose increase. Endpoints included change in glycated haemoglobin (HbA1c) at week 26 (primary); proportion of patients achieving HbA1c <7.0%; and changes in fasting plasma glucose (FPG), body weight and systolic blood pressure (SBP). Safety was assessed using AE reports.Overall, 85.4% of patients were titrated to canagliflozin 300 mg or matching placebo (mean ± standard deviation time to titration 6.2 ± 0.8 weeks). At week 26, canagliflozin (pooled 100 and 300 mg) demonstrated superiority in HbA1c reduction versus placebo (-0.91% vs. -0.01%; p < 0.001). Canagliflozin provided significant reductions in FPG, body weight and SBP compared with placebo (p < 0.001). The overall AE incidence was 39.8 and 44.4% for canagliflozin and placebo, respectively. Canagliflozin was associated with an increased incidence of genital mycotic infections.Titrated canagliflozin significantly improved HbA1c, FPG, body weight and SBP, and was generally well tolerated over 26 weeks in patients with T2DM as add-on to metformin and sitagliptin.

SUBMITTER: Rodbard HW 

PROVIDER: S-EPMC5089595 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin.

Rodbard H W HW   Seufert J J   Aggarwal N N   Cao A A   Fung A A   Pfeifer M M   Alba M M  

Diabetes, obesity & metabolism 20160607 8


<h4>Aims</h4>To evaluate the efficacy and safety of titrated canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin and sitagliptin.<h4>Methods</h4>In this randomized, double-blind study, patients with T2DM (N = 218) on metformin ≥1500 mg/day and sitagliptin 100 mg received canagliflozin 100 mg or placebo. After 6 weeks, the canagliflozin dose was increased from 100 to 300 mg (or from placebo to matching p  ...[more]

Similar Datasets

| S-EPMC4282288 | biostudies-literature
| S-EPMC3593184 | biostudies-literature
| S-EPMC6175352 | biostudies-literature
| S-EPMC5836931 | biostudies-literature
| S-EPMC4773675 | biostudies-literature
| S-EPMC5665259 | biostudies-literature
| S-EPMC4364855 | biostudies-other
| S-EPMC8029565 | biostudies-literature
| S-EPMC6593724 | biostudies-literature
| S-EPMC3825495 | biostudies-literature